Aspen Pharmacare Agrees to Sell European Ovestin Rights for EUR 197 Million
Aspen Pharmacare agreed to sell the European rights to Ovestin to Ennogen for EUR 197 million.
Related stories
CopperCorp sells Skyline to Bubalus; closing pending
CopperCorp has agreed to sell Skyline to Bubalus, but the transaction has not yet closed.
M impact | MNA | Nov 02, 2026, 11:04 AM UTC
Destination XL Group Temporarily Barred From Terminating Merger Agreement
Destination XL Group was temporarily enjoined from exercising its right to terminate its merger agreement with FBB Holdings.
M impact | MNA | Nov 02, 2026, 11:03 AM UTC
Public Policy Holding Deal Valued at Up to $80 Million
The deal includes $28 million initially and up to $52 million contingent.
M impact | MNA | Nov 02, 2026, 11:02 AM UTC
Public Policy Holding Agrees to Reevemark Consideration of Up to $80M
Public Policy Holding reported total consideration for Reevemark of up to $80 million.
M impact | MNA | Nov 02, 2026, 11:01 AM UTC
PPHC Announces Acquisition of Reevemark
M impact | MNA | Nov 02, 2026, 11:00 AM UTC
BMO Closes Acquisition of Euroz Hartleys' Australian Capital Markets Business
Bank of Montreal completed its acquisition of Euroz Hartleys' Australian capital markets business.
M impact | MNA | Nov 02, 2026, 10:59 AM UTC